共 25 条
[1]
[2]
[3]
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised; phase 3 trial[J] Sibylle Loibl;Joyce O'Shaughnessy;Michael Untch;William M Sikov;Hope S Rugo;Mark D McKee;Jens Huober;Mehra Golshan;Gunter von Minckwitz;David Maag;Danielle Sullivan;Norman Wolmark;Kristi McIntyre;Jose J Ponce Lorenzo;Otto Metzger Filho;Priya Rastogi;W Fraser Symmans;Xuan Liu;Charles E Geyer The Lancet Onc
[4]
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.[J] Traina Tiffany A;Miller Kathy;Yardley Denise A;Eakle Janice;Schwartzberg Lee S;O'Shaughnessy Joyce;Gradishar William;Schmid Peter;Winer Eric;Kelly Catherine;Nanda Rita;Gucalp Ayca;Awada Ahmad;Garcia-Estevez Laura;Trudeau Maureen E;Steinberg Joyce;Uppal Hirdesh;Tudor Iulia Cristina;Peterson Amy;Cortes Javier Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2
[5]
Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer[J] Cynthia Osborne;Jagathi D. Challagalla;Charles F. Eisenbeis;Frankie Ann Holmes;Marcus A. Neubauer;Nicholas W. Koutrelakos;Carlos A. Taboada;Sasha J. Vukelja;Sharon T. Wilks;Mary Ann Allison;Praveen Reddy;Scot Sedlacek;Yunfei Wang;Lina Asmar;Joyce O’Shaughnessy Clinical Breast Cancer 2018,
[6]
Phase II; multicentre; randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer[J] Yeon Hee Park;Seock-Ah Im;Sung-Bae Kim;Joo Hyuk Sohn;Keun Seok Lee;Yee Soo Chae;Ki Hyeong Lee;Jee Hyun Kim;Young-Hyuck Im;Ji-Yeon Kim;Tae-Yong Kim;Kyung-Hun Lee;Jin-Hee Ahn;Gun Min Kim;In Hae Park;Soo Jung Lee;Hye Sook Han;Se Hyun Kim;Kyung Hae Jung European Journal of Cancer 2017,
[7]
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.[J] Bardia Aditya;Mayer Ingrid A;Diamond Jennifer R;Moroose Rebecca L;Isakoff Steven J;Starodub Alexander N;Shah Nikita C;O'Shaughnessy Joyce;Kalinsky Kevin;Guarino Michael;Abramson Vandana;Juric Dejan;Tolaney Sara M;Berlin Jordan;Messersmith Wells A;Ocean Allyson J;Wegener William A;Maliakal Pius;Sharkey Robert M;Govindan Sereng
[8]
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.[J] Horiuchi Dai;Camarda Roman;Zhou Alicia Y;Yau Christina;Momcilovic Olga;Balakrishnan Sanjeev;Corella Alexandra N;Eyob Henok;Kessenbrock Kai;Lawson Devon A;Marsh Lindsey A;Anderton Brittany N;Rohrberg Julia;Kunder Ratika;Bazarov Alexey V;Yaswen Paul;McManus Michael T;Rugo Hope S;Werb Zena;Goga Andrei Nature medicine 2016,
[9]
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.[J] Nanda Rita;Chow Laura Q M;Dees E Claire;Berger Raanan;Gupta Shilpa;Geva Ravit;Pusztai Lajos;Pathiraja Kumudu;Aktan Gursel;Cheng Jonathan D;Karantza Vassiliki;Buisseret Laurence Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016,
[10]
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)[J] H. Bonnefoi;T. Grellety;O. Tredan;M. Saghatchian;F. Dalenc;A. Mailliez;T. L'Haridon;P. Cottu;S. Abadie-Lacourtoisie;B. You;M. Mousseau;J. Dauba;F. Del Piano;I. Desmoulins;F. Coussy;N. Madranges;J. Grenier;F.C. Bidard;C. Proudhon;G. MacGrogan;C. Orsini;M. Pulido;A. Gonçalves Annals of Oncology 2016,